Loading...

뉴스 목록

Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib

2022-05-12


Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib

Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib in adults with moderate to severe plaque psoriasis at the Spring Symposium of the European Society of Dermatology and Venereology . The results confirmed the durable efficacy and consistent safety profile of deucravicitinib treatment.

Currently, the marketing application of deucravicitinib for the treatment of adult patients with moderate to severe plaque psoriasis is under regulatory review in multiple regions, including the United States, Europe, and Japan. If approved, deucravicitinib would be the first approved selective allosteric tyrosine kinase 2 (TYK2) inhibitor. The drug will provide patients with moderate to severe plaque psoriasis a new oral treatment option to address current care gaps.


당사는 귀하의 웹사이트 이용을 더 잘 이해하기 위해 쿠키를 사용하고자 하며, 이는 향후 웹사이트 방문 시 귀하의 경험을 개선하는 데 도움이 될 것입니다. 브라우저 설정에서 이 설정을 변경할 수 있습니다. 쿠키 사용에 대한 자세한 내용은 개인정보 보호정책을 참조하세요.